Bayer has removed a protein therapeutic for hypertension and a treatment for diabetic neuropathic pain from its phase 1 pipeline.
- Home |
- Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug
Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug
- May 12, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
